コンテンツへスキップ
Merck

P1609000

フィトメナジオン

European Pharmacopoeia (EP) Reference Standard

別名:

ビタミンK1, 2-メチル-3-フィチル-1,4-ナフトキノン, 3-フィチルメナジオン, ビタミンK1(20), フィロキノン

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C31H46O2
CAS番号:
分子量:
450.70
Beilstein:
2568816
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

由来生物

synthetic

グレード

pharmaceutical primary standard

認証

EP

APIファミリー

phytomenadione

形状

solid

メーカー/製品名

EDQM

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

屈折率

n20/D 1.527 (lit.)

mp

−20 °C (lit.)

密度

0.984 g/mL at 25 °C (lit.)

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

SMILES記法

O=C(C1=CC=CC=C21)C(C)=C(C/C=C(CCC[C@@H](CCC[C@H](C)CCCC(C)C)C)\C)C2=O

InChI

1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1

InChI Key

MBWXNTAXLNYFJB-NKFFZRIASA-N

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Phytomenadione is a methyl napthoquinone derivative, and a naturally occurring fat soluble vitamin K1. It plays a key role in the maintenance of normal blood clotting mechanism and also in the prevention of hemorrhagic disease in newborns.

アプリケーション

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

その他情報

Sales restrictions may apply.

保管分類コード

11 - Combustible Solids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable


Choose from one of the most recent versions:

試験成績書(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Clinical Pharmacology, (11) (2012)
Development and validation of spectrophotometric methods for determination of phytomenadione in injection
Patel AS and Parikh KP
Current Research in Pharmaceutical Sciences, 26-30 (2012)
Bernard Laubscher et al.
European journal of pediatrics, 172(3), 357-360 (2012-11-30)
In 2003, the Swiss guidelines to prevent vitamin K deficiency bleeding (VKDB) were adapted. As two oral doses (2 mg, hour/day 4) of mixed micellar VK preparation had failed to abolish late VKDB, a third dose (week 4) was introduced.
Ellen C M Cranenburg et al.
Kidney international, 82(5), 605-610 (2012-06-01)
Vitamin K is essential for the activity of γ-carboxyglutamate (Gla)-proteins including matrix Gla28 protein and osteocalcin; an inhibitor of vascular calcification and a bone matrix protein, respectively. Insufficient vitamin K intake leads to the production of non-carboxylated, inactive proteins and
Rogier Caluwé et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(7), 1385-1390 (2013-11-29)
Haemodialysis patients suffer from accelerated vascular calcification. The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification. Haemodialysis patients have high levels of the inactive form of MGP (desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and may benefit

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)